Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up by Alessia Buglioni, Valentina Cannone, S. Jeson Sangaralingham, Denise M. Heublein, Christopher G. Scott, Kent R. Bailey, Richard J. Rodeheffer, Riccardo Sarzani, John C. Burnett Jr

Get full text

CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. by Fernando L Martin, S Jeson Sangaralingham, Brenda K Huntley, Paul M McKie, Tomoko Ichiki, Horng H Chen, Josef Korinek, Gerald E Harders, John C Burnett

Get full text

A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction by Martin, Fernando L., Huang, Ying Ying, Venkatraman, Subbu Subramanian, Burnett, John C., Chen, Horng H., Lim, Soo Ghim, Jeson Sangaralingham, S., Ameenuddin, Syed, Ng, Xu Wen

Get full text
Get full text

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation by Xiao Ma, Seethalakshmi R. Iyer, Xiaoyu Ma, Shawn H. Reginauld, Yang Chen, Shuchong Pan, Ye Zheng, Dante G. Moroni, Yue Yu, Lianwen Zhang, Valentina Cannone, Horng H. Chen, Carlos M. Ferrario, S. Jeson Sangaralingham, John C. Burnett

Get full text

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker by Nicholas Y. Tan, MD, MS, Yihong Deng, PhD, Xiaoxi Yao, PhD, MPH, Lindsey R. Sangaralingham, MPH, Nilay D. Shah, PhD, Andrew D. Rule, MD, John C. Burnett, Jr., MD, Shannon M. Dunlay, MD, MS, S. Jeson Sangaralingham, MS, PhD

Get full text